Skip to main content

Table 2 Clinicopathologic features and PTHrP expression

From: Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome

 

PTHrP positive

PTHrP negative

χ2

P value

No. (%)

No. (%)

Age

    

 ≤55

146 (53.9 %)

121 (53.5 %)

0.006

0.941

 >55

125 (46.1 %)

105 (46.5 %)

  

Tumor size

    

 ≤2 cm

133 (49.1 %)

145 (64.2 %)

11.372

0.001

 >2 cm

138 (50.9 %)

81 (35.8 %)

  

Skin involvementa

    

 No

223 (82.3 %)

196 (86.7 %)

1.834

0.176

 Yes

48 (17.7 %)

30 (13.3 %)

  

LN metastasis

    

 No

154 (57.7 %)

148 (67.6 %)

5.014

0.025

 Yes

113 (42.3 %)

71 (32.4 %)

  

 Unknown

4

7

  

Histologic grade

    

 ≤II

187 (70.8 %)

165 (74.7 %)

0.885

0.347

 >II

77 (29.2 %)

56 (25.3 %)

  

 Unknown

7

5

  

Clinical stage

    

 I

95 (35.1 %)

100 (44.2 %)

6.937

0.031

 II

116 (42.8 %)

94 (41.6 %)

  

 III

60 (22.1 %)

32 (14.2 %)

  

ER

    

 (−)

78 (29.2 %)

56 (26.9 %)

0.303

0.582

 (+)

189 (70.8 %)

152 (73.1 %)

  

 Unknown

4

18

  

HER-2

    

 (−)

98 (40.3 %)

79 (39.7 %)

0.018

0.893

 (+)

145 (59.7 %)

120 (60.3 %)

  

 Unknown

28

27

  

Tumor type

    

 IDCb

231 (85.2 %)

192 (85.0 %)

0.008

0.929

 Non-IDCc

40 (14.8 %)

34 (15.0 %)

  

TGF-β

    

 (−)

116 (42.8 %)

107 (47.3 %)

1.027

0.311

 (+)

155 (57.2 %)

119 (52.7 %)

  
  1. askin involvement: edema, redness, nodularity, or ulceration
  2. bIDC, invasive ductal carcinoma
  3. cNon-IDC: invasive lobular carcinoma, mucinous or colloid carcinoma, medullary carcinoma, metaplastic carcinoma